The brain's immune cells activate, releasing inflammatory molecules that breach the barrier
For decades, the search for a drug that could protect the brain after stroke has ended in disappointment — promising in the laboratory, silent in the clinic. Now Hungarian researchers have found an unexpected candidate in DMT, a molecule the human body already produces, which appears to defend neural tissue through two simultaneous mechanisms: repairing the blood-brain barrier and quieting the inflammatory cascade that turns a stroke's initial injury into lasting devastation. The finding, emerging from Budapest's HUN-REN BRC Institute and Semmelweis University, does not yet promise a cure, but it reopens a door that many had quietly closed.
- Every minute after a stroke, neurons die — and the inflammation that follows can be as destructive as the original blockage, yet no approved treatment addresses it.
- Current therapies like clot-busting drugs operate within a razor-thin time window and leave the subsequent inflammatory storm entirely untreated.
- DMT, a psychoactive compound naturally present in the human brain, reduced infarct size, prevented swelling, and restored blood-brain barrier function in rat stroke models — a dual action no previous neuroprotective agent has achieved in clinical translation.
- The molecule suppressed inflammatory cytokines and calmed the brain's resident immune cells through sigma-1 receptors, suggesting a coordinated biological defense rather than a single-point intervention.
- Clinical trials are now underway, carrying the weight of a field long accustomed to laboratory breakthroughs that never reach patients.
Stroke is medicine's stubborn adversary. Within minutes of a blockage or bleed, neurons begin to die — and the damage does not stop there. The brain's immune system activates, inflammatory molecules breach the blood-brain barrier, and peripheral immune cells flood in, compounding the original injury. The human cost is immense: lasting disability, fractured families, and healthcare burdens that stretch across years. Despite decades of effort, no neuroprotective drug has successfully crossed from animal research into routine clinical use.
Researchers at Hungary's HUN-REN BRC Institute of Biophysics and Semmelweis University's Cardiovascular Center have now turned attention to an unlikely candidate: DMT, or dimethyltryptamine — a psychoactive molecule found naturally in plants, animals, and the human brain itself. Their study, published in Science Advances, reveals that DMT acts on two of stroke's most destructive processes at once.
In rat stroke models, DMT meaningfully reduced the size of damaged brain tissue and prevented swelling. In both animal and cell-culture experiments, it restored the structure of the compromised blood-brain barrier while simultaneously suppressing the inflammatory cytokines that drive secondary injury. It also reduced activation of microglia — the brain's own immune cells — through sigma-1 receptors. The result was not a single targeted intervention but something more like a coordinated biological defense.
Lead researchers Maria Deli, Marcell László, and Judit Vigh each noted what makes this finding distinct: previous neuroprotective agents have failed precisely because stroke's injury cascade involves multiple overlapping pathways. DMT's dual mechanism — barrier repair alongside inflammation control — addresses that complexity in a way single-target drugs have not.
Clinical trials are currently underway. The road from promising animal data to proven human therapy is long and uncertain, and this field has known many disappointments. But for a disease that touches millions and has resisted intervention for so long, even a credible new direction carries considerable weight.
Stroke remains one of medicine's most intractable problems. A person suffers a blockage or bleed in the brain, and within minutes, neurons begin to die. The damage cascades—inflammation spreads, the brain swells, and what emerges is often a patient fundamentally altered, burdened with disability that ripples outward to family and society. The costs, both human and financial, are staggering. Yet despite decades of research into neuroprotective agents, none has successfully made the leap from laboratory promise to routine clinical use.
Now researchers at Hungary's HUN-REN BRC Institute of Biophysics and Semmelweis University's Cardiovascular Center have found something unexpected in an old molecule. DMT—dimethyltryptamine, a naturally occurring psychoactive compound found in plants and mammals, including the human brain—appears to shield neural tissue from stroke's worst effects. The findings, published in Science Advances, suggest a dual mechanism of action that addresses two of stroke's most destructive processes simultaneously.
When a stroke occurs, the damage unfolds in stages. The initial blockage kills neurons directly, but what follows is equally devastating: the brain's immune cells activate, releasing inflammatory molecules that breach the blood-brain barrier—the delicate membrane that normally protects the brain from circulating immune cells and toxins. Once that barrier fails, peripheral white blood cells flood in, amplifying inflammation and triggering secondary injury that can be as damaging as the stroke itself. Current treatments, like intravenous clot-busting drugs and mechanical clot removal, work only within a narrow time window and carry serious risks. They do nothing to stop the inflammation that unfolds afterward.
The Hungarian team discovered that DMT works on both fronts. In rat stroke models, the compound significantly reduced the size of the infarcted area and prevented brain swelling. In both animal experiments and cell cultures, DMT restored the structure and function of the damaged blood-brain barrier while simultaneously dampening the inflammatory cascade. It suppressed the production of inflammatory cytokines in brain endothelial cells and peripheral immune cells, and it reduced activation of microglia—the brain's resident immune cells—through sigma-1 receptors. The effect was not a single intervention but a coordinated protection: barrier repair plus inflammation control.
Maria Deli, one of the study's lead authors, reflected on the finding with a sense of wonder at nature's solutions. Her colleague Marcell László emphasized the significance of DMT's dual action in reducing both the physical damage and the inflammatory response. Judit Vigh, also part of the team, noted that this two-pronged approach could complement existing treatments in ways previous neuroprotective agents have failed to do.
The challenge in stroke research has always been complexity. The cascade of injury involves multiple cell types, overlapping pathways, and feedback loops that reinforce one another. Targeting a single component has proven insufficient. DMT's appeal lies in its ability to address the problem at multiple levels—protecting the barrier while quieting the inflammatory storm. Whether this translates to clinical benefit remains to be seen. Clinical trials on DMT are currently underway, and researchers are investigating its long-term effects. If successful, it would represent a rare breakthrough in a field littered with failed promises.
Notable Quotes
It is remarkable how we can always turn to nature to find ingenious solutions— Maria Deli, lead researcher, Semmelweis University
The dual action of DMT, protecting the blood-brain barrier and reducing brain inflammation, offers a novel and complex approach that could complement existing treatments— Judit Vigh, HUN-REN BRC Institute of Biophysics
The Hearth Conversation Another angle on the story
Why has neuroprotection been so difficult? We've known stroke is devastating for decades.
Because stroke isn't one problem—it's a cascade. You stop the clot, but then inflammation takes over. You suppress inflammation, but the barrier's already broken. Every agent that worked in the lab failed when it met the full complexity of the living brain.
And DMT is different because?
It doesn't choose. It protects the barrier and quiets the inflammation at the same time. It's not fighting one piece of the problem; it's addressing the architecture of the damage itself.
But it's a psychoactive drug. Won't there be resistance to using it clinically?
That's the real question. The molecule is naturally present in the human brain already. The trials will tell us whether the dose needed for neuroprotection causes the effects people associate with DMT, or whether it works at levels where it's purely protective.
What happens if the trials succeed?
Then stroke treatment changes. Not as a replacement for clot removal, but as something that comes after—something that stops the secondary damage that current medicine can't touch. That's the gap it fills.